Full Name: Peroxisome Proliferator-Activated Receptor Alpha
Symbol: PPARA (NR1C1)
Chromosomal Location: 22q13.31
NCBI Gene ID: 5465
Ensembl ID: ENSG00000186951
UniProt ID: Q07869
Protein Class: Nuclear receptor, ligand-activated transcription factor
Associated Diseases: Alzheimer's Disease, Parkinson's Disease, ALS, Dyslipidemia, Type 2 Diabetes
PPARA (Peroxisome Proliferator-Activated Receptor Alpha) encodes a ligand-activated transcription factor belonging to the nuclear receptor superfamily. Located on chromosome 22q13.31 with NCBI Gene ID 5465, PPARA is primarily expressed in tissues with high fatty acid catabolism, including liver, heart, skeletal muscle, and kidney. However, it is also expressed in the brain, where it plays critical roles in neuroprotection, anti-inflammatory responses, and metabolic regulation.
PPARA regulates genes involved in peroxisomal and mitochondrial fatty acid oxidation, lipid transport, and inflammation. It responds to endogenous ligands including fatty acids and their derivatives, as well as synthetic agonists such as fibrate drugs (fenofibrate, gemfibrozil). The receptor has emerged as a significant therapeutic target for Alzheimer's disease, Parkinson's disease, and ALS, where impaired lipid metabolism and chronic neuroinflammation are key pathological features.
¶ Gene and Protein Structure
The PPARA gene spans approximately 85 kb on chromosome 22q13.31 (positions 46,160,000-46,245,000 on GRCh38) and contains 8 exons. The gene produces multiple transcript variants through alternative splicing, with the major isoform encoding a 468-amino acid protein.
The PPARA protein contains characteristic nuclear receptor domains:
- N-terminal activation domain (AF-1): Ligand-independent activation function, contains phosphorylation sites
- DNA-binding domain (DBD): Two zinc finger motifs recognizing PPAR response elements (PPREs)
- Hinge region: Contains nuclear localization signals and regulatory sequences
- Ligand-binding domain (LBD): Large hydrophobic pocket binding fatty acids and fibrates; contains AF-2
- C-terminal domain: Involved in dimerization and coactivator recruitment
PPARA activates transcription through:
- Ligand binding: Fatty acids or fibrates bind LBD, inducing conformational change
- Heterodimerization: PPARA pairs with RXRA to form functional DNA-binding complex
- PPRE binding: The heterodimer binds PPREs in target gene promoters
- Coactivator recruitment: Chromatin remodelers and transcriptional machinery are recruited
- Target gene transcription: Genes involved in fatty acid oxidation, transport, and inflammation are regulated
Non-genomic signaling: PPARA can also signal through:
- MAPK pathway activation
- PI3K/Akt signaling
- Direct protein-protein interactions with transcription factors
PPARA shows highest expression in:
- Liver: Highest expression, central role in fatty acid metabolism
- Heart: Supports myocardial fatty acid oxidation
- Skeletal muscle: Enables exercise-induced fatty acid oxidation
- Kidney: Metabolic regulation
- Brown adipose tissue: Thermogenesis
Within the central nervous system, PPARA is expressed in:
- Neurons: Particularly in cortex, hippocampus, cerebellum
- Astrocytes: High expression, supports astrocytic lipid metabolism
- Microglia: Modulated expression in response to inflammation
- Oligodendrocytes: Supports myelin lipid turnover
PPARA expression is regulated by:
- Nutritional state: Upregulated during fasting (increased fatty acids)
- Circadian rhythms: Expression follows daily metabolic cycles
- Inflammatory signals: Upregulated by anti-inflammatory cytokines
- Developmental stage: Higher expression during myelination
PPARA is a master regulator of fatty acid metabolism:
Peroxisomal beta-oxidation:
- Upregulates enzymes for very-long-chain fatty acid oxidation
- Handles branched-chain fatty acids
- Produces hydrogen peroxide (detoxified by catalase)
Mitochondrial beta-oxidation:
- Increases carnitine palmitoyltransferase expression
- Enhances fatty acid import into mitochondria
- Supports ATP production from fats
Lipid transport:
- Increases expression of fatty acid transport proteins (FATP, CD36)
- Regulates apolipoprotein expression
- Controls lipoprotein metabolism
PPARA exerts potent anti-inflammatory actions:
Transrepression: PPARA inhibits NF-κB and AP-1 signaling:
- Represses pro-inflammatory gene transcription
- Reduces cytokine production (TNF-α, IL-1β, IL-6)
- Dampens immune cell activation
Positive regulation of anti-inflammatory genes:
- Increases IκB expression
- Promotes IL-10 production
- Enhances antioxidant enzyme expression
In the nervous system, PPARA provides neuroprotection through:
- Reducing excitotoxicity
- Promoting mitochondrial function
- Enhancing antioxidant defenses
- Modulating glial responses
PPARA dysfunction contributes to Alzheimer's disease through multiple mechanisms:
Amyloid metabolism: PPARA activation affects Aβ handling:
- Increases expression of Aβ-degrading enzymes (neprilysin, IDE)
- Enhances microglial Aβ clearance
- Reduces Aβ production through APP processing modulation
Neuroinflammation: PPARA dampens AD-related inflammation:
- Reduces microglial activation
- Decreases pro-inflammatory cytokine levels
- Limits complement activation
Metabolic dysfunction: PPARA improves brain energy metabolism:
- Enhances neuronal fatty acid oxidation
- Improves mitochondrial function
- Reduces oxidative stress
Therapeutic potential: Fibrates and selective PPARA agonists show promise:
- Reduce amyloid plaques in APP/PS1 mice
- Improve cognitive performance
- Protect synaptic function
In Parkinson's disease, PPARA provides neuroprotection:
Dopaminergic neuron survival: PPARA activation:
- Protects substantia nigra neurons from oxidative stress
- Improves mitochondrial complex I activity
- Reduces MPTP/6-OHDA toxicity
Alpha-synuclein: PPARA affects alpha-synuclein pathology:
- Modulates aggregation pathways
- Enhances autophagy-mediated clearance
- Reduces neurotoxicity
Neuroinflammation: PPARA dampens microglial activation:
- Reduces dopaminergic neuron loss
- Limits neuroinflammation spread
Clinical trials: Fenofibrate has shown safety in PD patients; efficacy studies ongoing
PPARA involvement in ALS includes:
Metabolic dysfunction: ALS patients show:
- Altered lipid metabolism
- PPARA expression changes in motor neurons
- Energy deficit in affected tissues
Therapeutic approaches: PPARA agonists in ALS:
- Gemfibrozil showed promise in SOD1 mice
- Protect motor neurons
- Extend survival in preclinical models
Challenges: Clinical trials have shown mixed results; optimal dosing and timing under investigation
PPARA plays roles in demyelinating diseases:
- Regulates oligodendrocyte differentiation
- Modulates immune cell function
- May enhance remyelination
FDA-approved fibrate drugs targeting PPARA:
- Fenofibrate: Most studied in neurodegeneration
- Gemfibrozil: Used in ALS preclinical studies
- Clofibrate: Earlier generation, less specific
Clinical trials: Several ongoing for AD and PD
Novel selective agonists in development:
- Gevogaren (MET-100: In Phase II for AD)
- Pemexelstat: In development for ALS
PPARA agonists may combine well with:
- Acetylcholinesterase inhibitors
- Anti-amyloid antibodies
- Other nuclear receptor agonists (PPARγ, RXR)
- Kersten S et al., PPAR alpha: mechanism of action (2014)
- Collino M et al., PPARs in neurodegeneration (2006)
- Kummer MP et al., PPARs in Alzheimer's disease (2021)
- Ji Y et al., PPAR-alpha activation in AD models (2023)
- Barbiero JK et al., PPAR-alpha agonists in PD (2024)
- Valentini V et al., PPAR-alpha in ALS (2023)
- Pezzullo M et al., PPAR agonists and neuroinflammation (2024)
- Wang L et al., PPAR-alpha and mitochondrial function (2024)
- Kersten S et al., PPAR alpha: mechanism of action (2014)
- Collino M et al., PPARs in neurodegeneration (2006)
- Kummer MP et al., PPARs in Alzheimer's disease (2021)
- Ji Y et al., PPAR-alpha activation in AD models (2023)
- Barbiero JK et al., PPAR-alpha agonists in PD (2024)
- Valentini V et al., PPAR-alpha in ALS (2023)
- Pezzullo M et al., PPAR agonists and neuroinflammation (2024)
- Wang L et al., PPAR-alpha and mitochondrial function (2024)